In Reply Dauby’s comments highlight the active progress in group B Streptococcus (GBS) vaccine development. The study he cites by Buurman and colleagues,1 published the day after publication of the study by Francois Watkins and collagues2 and my accompanying Invited Commentary,3 describes Pfizer’s development and preclinical studies of a novel hexavalent capsular polysaccharide (CPS) conjugate vaccine (GBS6) for the prevention of neonatal GBS infections by maternal immunization.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Barshak MB. Vaccination for the Prevention of Group B Streptococcus Infection in Nonpregnant Adults—Reply. JAMA Intern Med. 2019;179(7):999. doi:10.1001/jamainternmed.2019.1587
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: